Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. This technology represents a novel, next-generation approach to the management of human genetic diseases and offers the potential to improve treatment options for many patients. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. The company believes pharmacological chaperone technology has broad applicability and expects to expand the portfolio to include other diseases of neurodegeneration, metabolic diseases, and oncology. Founded in 2002, Amicus has assembled an outstanding leadership team that includes scientific, medical, regulatory, and business professionals with successful track records of developing and bringing to market drugs for genetic diseases. Amicus continues to develop its pharmacological chaperone technology and has built a significant intellectual property portfolio along with its robust clinical and preclinical pipeline. Amicus has a fast-paced, high-energy, entrepreneurial team environment where employees are encouraged to be innovative and resourceful. Amicus seeks high-caliber, talented individuals with a passion to succeed.
Show more

Employee Rating

3.2More
TypePublic
HQCranbury Township, US
Founded2002
Size (employees)263 (est)
Websiteamicusrx.com
Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury Township, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Amicus Therapeutics

William D. Chip Baird

William D. Chip Baird

CFO
Bradley L Campbe

Bradley L Campbe

COO
Jeffrey P Castelli

Jeffrey P Castelli

Vp
Enrique Diloné

Enrique Diloné

Vp
Jay A Barth

Jay A Barth

Chief Medical Officer
Hung Do

Hung Do

Senior Vice President
Show more

Amicus Therapeutics Office Locations

Amicus Therapeutics has offices in Cranbury Township, Puteaux, Munich, Denham and in 1 other location
Cranbury Township, (HQ)
1 Cedar Brook Drive
Puteaux,
Tour Défense 2000
Show all (5)
Report incorrect company information

Amicus Therapeutics Financials and Metrics

Amicus Therapeutics Revenue

Amicus Therapeutics's revenue was reported to be $36.93 m in FY, 2017
USD

EBIT (Q3, 2018)

(156.2m)

Market capitalization (4-Dec-2018)

1.9b

Closing stock price (4-Dec-2018)

9.9

Cash (30-Sep-2018)

201.8m
Amicus Therapeutics's current market capitalization is $1.9 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

363.0k1.2m5.0m36.9m

Revenue growth, %

(99%)(100%)

Cost of goods sold

833.0k6.2m

Gross profit

4.1m30.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Revenue

39.0k456.0k475.0k293.0k456.0k475.0k293.0k

Cost of goods sold

344.0k775.0k1.8m

General and administrative expense

4.6m5.2m4.8m5.3m6.4m8.3m15.4m15.7m19.3m17.5m19.1m21.6m

R&D expense

10.1m10.0m10.0m12.0m16.1m17.2m21.0m23.4m18.3m32.5m30.9m40.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

43.6m24.1m69.5m187.0m49.1m

Accounts Receivable

1.3m9.5m

Inventories

5.5m2.9m2.6m3.4m4.6m

Current Assets

88.3m154.6m216.6m340.1m392.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

30.0m27.5m41.9m19.7m28.8m249.0m19.4m23.5m63.7m33.1m44.8m37.4m64.1m114.3m73.3m201.8m

Accounts Receivable

864.0k1.9m3.8m6.0m10.8m15.1m14.2m

Inventories

194.0k3.3m3.7m3.9m7.3m8.1m7.8m6.3m

Current Assets

64.3m73.5m79.4m87.2m151.3m365.0m240.1m168.5m217.7m221.7m296.2m241.0m431.0m592.0m576.2m601.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(59.6m)(68.9m)(132.1m)(200.0m)(284.0m)

Depreciation and Amortization

1.7m1.5m1.8m3.2m3.6m

Inventories

(3.2m)2.3m308.0k(3.7m)(897.0k)

Accounts Payable

6.2m15.5m7.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(47.4m)(15.9m)(30.6m)(47.7m)(24.3m)(51.4m)(89.2m)(43.7m)(94.7m)(141.4m)(55.0m)(103.1m)(214.8m)(49.9m)(111.8m)(270.9m)

Depreciation and Amortization

1.3m412.0k808.0k1.2m508.0k861.0k1.3m673.0k1.4m2.3m823.0k1.6m2.5m969.0k1.9m3.0m

Inventories

(207.0k)(3.5m)(243.0k)(351.0k)(3.4m)(3.3m)(3.4m)(2.0m)

Accounts Payable

(679.0k)(987.0k)(155.0k)1.2m(551.0k)459.0k14.1m(9.8m)(8.2m)(2.9m)(1.3m)
USDY, 2018

Financial Leverage

2 x
Show all financial metrics
Report incorrect company information

Amicus Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Amicus Therapeutics News and Updates

Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

CRANBURY, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, Arizona on Wednesday, November 14…

Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates

U.S. Galafold ® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch

Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018

CRANBURY, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 5, 2018 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2018.

Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study at 23rd International Annual Congress of the World Muscle Society

Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue Out to Month 18 for both ERT-Naïve and ERT-Switch Patients

Amicus Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology

CRANBURY, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, …

Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders

License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout)Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to Transform the Lives of 10,000+ Children with Fatal Genetic Diseases             Inclu…
Show more
Report incorrect company information

Amicus Therapeutics Blogs

Amicus Therapeutics to Host Analyst Day 2018 Today in New York City

Management and External Thought Leaders to Highlight Robust Portfolio of Novel Therapies for Rare Metabolic Diseases Webcast Scheduled from 8:30am – 12:30pm E.T. CRANBURY, N.J. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASDAQ: FOLD), a global biotechnology company focused on

Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies

Collaboration Focuses on Four Genetic Disorders: Pompe, Fabry, CDKL5 and One Additional Undisclosed Rare Metabolic Disorder Combines Amicus Expertise in Protein Engineering with Penn’s AAV Vector Technology, Manufacturing and Immunology Capabilities Leverages The Wilson Lab’s Extensive

Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society

CRANBURY, N.J. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe disease will be included at the 23rd International Congress of the World Muscle Society , to be held

Amicus Therapeutics 2018 Investor Day

Amicus Therapeutics 2018 Investor Day ronryan.teano@… Thu, 09/20/2018 - 16:28 Amicus Therapeutics 2018 Analyst Day Display "add to calendar" true Event Type Analyst Meeting Event Categories Default Cale…

Amicus Therapeutics Company Life and Culture

Report incorrect company information

Amicus Therapeutics Frequently Asked Questions

  • When was Amicus Therapeutics founded?

    Amicus Therapeutics was founded in 2002.

  • Who are Amicus Therapeutics key executives?

    Amicus Therapeutics's key executives are William D. Chip Baird, Bradley L Campbe and Jeffrey P Castelli.

  • How many employees does Amicus Therapeutics have?

    Amicus Therapeutics has 263 employees.

  • What is Amicus Therapeutics revenue?

    Latest Amicus Therapeutics annual revenue is $36.9 m.

  • What is Amicus Therapeutics revenue per employee?

    Latest Amicus Therapeutics revenue per employee is $140.4 k.

  • Who are Amicus Therapeutics competitors?

    Competitors of Amicus Therapeutics include Sanofi Genzyme, Mast Therapeutics and Zogenix.

  • Where is Amicus Therapeutics headquarters?

    Amicus Therapeutics headquarters is located at 1 Cedar Brook Drive, Cranbury Township.

  • Where are Amicus Therapeutics offices?

    Amicus Therapeutics has offices in Cranbury Township, Puteaux, Munich, Denham and in 1 other location.

  • How many offices does Amicus Therapeutics have?

    Amicus Therapeutics has 5 offices.